CLINICAL TRIALS

RALES

Summary: Evaluated spironolactone versus placebo in patients with New York Heart Association (NYHA) functional class IV at some point, treated with ACE inhibitors and diuretics, and ejection fraction of < 35%. The primary endpoint of death from any cause was reduced. There was a reduction in sudden death and an improvement in symptoms across all subgroups.